Good you I and then Results an afternoon, thank on review and XXXX Third update Business Financial our Quarter recent Update pipeline Call. our will activities. with for begin and joining TRACON's
discuss X that, September months Following will XX, Brown, for results XXXX. Chief our financial Scott ended the Officer, Financial our X and
your Finally, questions. conclude we taking by will
trial. patients blinded with I'll September, begin and on by update Monitoring rate ongoing initial patients review reviewed the ENVA In with C X.X% in pivotal Committee our continued central Data XX% XX response investigator and single-agent treated the efficacy ENVASARC independent progress The data in an interim review. single-agent of with objective was by the treatment. safety from cohort XX ENVA
The were assessed futility generally which review, confirmed the all and responses, well ENVA response of prespecified by satisfied was monotherapy rule than rate central tolerated. more
review X additional patients of as then, XX response than Importantly, the DMC more planned. And greater continue months. is by have median study recommended The since duration central than enrolled.
expect of on release data accrual track to and ENVASARC response the trial updated the the end year. are fourth of before XXXX of the in rate quarter We pivotal complete to
endpoint. of XX months of show central X exceed As or UPS MFS, of X or greater statistically objective by reminder, response secondary FDA-approved a in response patients order review. in response a out with responses of confirmed refractory key is the XX.XX% must the rate treatment ENVASARC objective X% duration in to Votrient, endpoint for patients the an only objective Median rate than primary
be for the and to ENVA liver has both warning toxicity. efficacious with box Votrient, a in demonstrate than fatal ENVASARC potential is Our drug a safer goal black more that to
responses. the we FDA we or Based a refractory approach on a BLA filing ENVA. plan are to for soon single-agent Furthermore, checkpoint as trials MFS, of inhibitors rate from UPS determine to strategy data as response X targeting other in discuss XX% we
received in soft observed that As designation progressed in X designations that subtypes expedite in data refractory regulatory These lines drug we provide ENVA. activity orphan ENVA subtypes designation provide MFS. sarcoma track and received efficacy in MFS of on or on of prior and and X and a sarcoma is tissue based have commercialization ENVASARC. advantages designed and of might for have reminder, therapy, sarcoma of fast the important review ENVASARC UPS UPS safety to the
the goal of the subtypes therapy in sarcoma. of of that We the in of therefore, Doxorubicin the of setting most initiate combination the patients. UPS frontline We, and pivotal doxorubicin. to subtypes, the ENVA with sarcoma of to newly treatment frontline the and common the completion will is MFS doxorubicin sarcoma trial to best diagnosed a approval ENVA ENVASARC also ENVA be for enrollment trial. that The sarcoma in plan and strategy following including trial determine the respond common have used a for of
randomized potential require demonstrate trial, we of pivotal accelerated will Assuming expect ENVASARC positive results approval the trial benefit. in survival FDA a the ENVA, a to
sarcoma trial We MFS as single-agent and with therapy respond and as as to UPS expect subtypes doxorubicin. expected compare with doxorubicin ENVA Phase with to will would III patients with endpoint. to trial ENVA shown enroll this doxorubicin the potential PFS to This well post-approval other be
the sarcoma. meeting to a We or review expected the the expected expect the for frontline at data in of design FDA from to ENVASARC ENVA of submission approval refractory pre-BLA trial of potential with time accelerated discuss
in at potential peak sales approval $XXX MFS. refractory not annual ENVA anticipated to million in important parity sarcoma is ENVA revenues is in forecasted following with pricing solely UPS It the and understand the
designed create and is supplemental patients neoadjuvant strategy ENVA development by settings with frontline, the opportunity seeking Our adjuvant BLAs. broadly the for sarcoma clinical to in benefit to
DNA TRCXXX is Phase with an turn financially trial lung cancer standard TRCXXX Institute. of inhibitor, now National a II to cell will radiation. of The X The in our durvalumab by We therapy with that chemo Stage pemetrexed, non-squamous non-small combination the consolidated damage randomized care to sponsoring cooperative repair to Cancer followed benefit adding trial ongoing radiation enroll and TRCXXX treatment. research treatment NCI and assess XX is III supported assessing patients in maintenance development agreement cisplatin arm current will the of through
improvement year, expected trial an in are The primary in is XX% endpoint for in XXXX. final X of open XX%. the PFS, to at and are to enrollment sites the the designed from and detect results PFS U.S. is trial X
update I CRO-independent product discuss will of shift our our from development pipeline PDP. now we call which research, our to platform
trials pipeline We offering who This trials. companies continue more plans year, what multiple partner or to conduct a of trial of platform clinical pay PDP license CRO. a to emerging this we cost reporting an otherwise our to expect they our would being expect management, may with the to potentially management our and a collaborator one to of a data company at execute conduct enable than less safety include would that advanced with X/X of ideal
cost run do allow per the of to A at estimated to PDP $XXX,XXX would TRACON, license of for trials an a partner clinical patient. approximately we be as expected
from $XXX,XXX $XX be partner. charges CRO typical could our trial or a a more on the million per up to XXX-patient patient, the As licensing PDP for approximately potential savings
our increased the trials to execution in-house we of pace that advantages team. addition by running In expected speed TRACON enrollment of trial of and using enjoy
on update an to now the I-Mab. from arbitration work Turning
in of million $XXX,XXX success-based write-off our the from invoices of $X.X the held arbitration account may In of been and we from amount I-Mab brings the $X.X now satisfaction received the in approximately legal net $XX arbitration award, a which matter is the attorneys. September, had to July discussions from remember, fees million, million as were amount in collected client disputed on we in attorneys proceeds client trust of of due. to the deferred in predicated was closed. addition This firm the from successfully million and As you by $X the total trust the
will this update Scott on an At our time, provide financials.
